Can prednisone be initiated for Bell's palsy in a woman who is in active labor?

Prednisone for Bell's Palsy in Active Labor

Yes, prednisone can and should be initiated for Bell's palsy in a woman who is in active labor, as the benefits of treatment for Bell's palsy significantly outweigh the minimal risks of short-term corticosteroid exposure at this stage of pregnancy.

Evidence Supporting Prednisone Use

Efficacy for Bell's Palsy

• Prednisone is highly effective for Bell's palsy, with the landmark BELLS trial demonstrating 83.0% complete recovery at 3 months with prednisolone versus 63.6% without treatment (difference +19.4%, NNT=6), and 94.4% recovery at 9 months versus 81.6% (difference +12.8%, NNT=8) 1
• Treatment should be initiated within 72 hours of symptom onset for maximum benefit, with one-half of patients in the BELLS trial starting within 24 hours 1
• The standard regimen is prednisolone 50 mg daily for 10 days, with tapering 1

Safety Profile in Late Pregnancy and Labor

Prednisone/prednisolone are considered safe in pregnancy, particularly in the third trimester and during labor:

• Prednisone and prednisolone are not associated with increased rates of major birth defects and can be used during pregnancy when needed to control active disease 2
• These non-fluorinated corticosteroids are largely metabolized by the placenta, with only 10% reaching the fetus 2
• The greatest teratogenic risk is in the first trimester (particularly weeks 4-5 during organogenesis); at term/during active labor, organogenesis is complete and structural malformation risk is essentially zero 3
• Short-term use (10 days) at this stage poses minimal risk compared to untreated Bell's palsy, which can result in permanent facial paralysis affecting quality of life 1

Specific Considerations for Active Labor

Key safety points for initiating treatment during active labor:

• Daily doses ≤50 mg for short duration (10 days) are associated with low maternal and fetal risk 2
• Prednisone is compatible with breastfeeding, with very little entering breast milk 4
• The primary maternal concerns with corticosteroids—gestational diabetes, preeclampsia, and pregnancy-associated osteoporosis—are related to prolonged use at higher doses, not short-term treatment 2
• At the point of active labor, concerns about preterm birth and low birth weight are no longer relevant 2

Clinical Algorithm for Treatment

Immediate management:

1. Initiate prednisolone 50 mg orally daily for 10 days if presenting within 72 hours of Bell's palsy symptom onset 1
2. No need to delay treatment for delivery—the 10-day course can be started immediately 1
3. Reassure the patient that breastfeeding is safe and compatible with this treatment 4

Monitoring considerations:

• No special fetal monitoring is required beyond routine labor management 2
• Monitor maternal blood glucose if the patient has risk factors for diabetes, though short-term risk is minimal 2
• Standard labor anesthesia (epidural/spinal) can proceed normally—corticosteroids do not affect platelet count or coagulation in this context 2

Common Pitfalls to Avoid

Critical errors to prevent:

• Do not withhold effective treatment due to unfounded concerns about late-pregnancy corticosteroid exposure—the risk-benefit ratio strongly favors treatment 2, 1
• Do not use dexamethasone or betamethasone for Bell's palsy treatment—these fluorinated corticosteroids cross the placenta extensively and are reserved for fetal indications only; use prednisone/prednisolone instead 5
• Do not delay treatment waiting for delivery—Bell's palsy treatment is time-sensitive, with best outcomes when started within 72 hours 1
• Do not add aciclovir—the BELLS trial showed no benefit from antiviral therapy either alone or in combination with prednisolone 1

Nuances and Strength of Evidence

The evidence base is robust: the BELLS trial 1 is a large, well-designed randomized controlled trial (n=496) that provides Class I evidence for prednisolone efficacy in Bell's palsy. The rheumatology guidelines 2 consistently support prednisone/prednisolone safety in pregnancy when clinically indicated, with the caveat that prolonged high-dose use should be avoided when possible—which does not apply to the 10-day Bell's palsy treatment course.

The convergence of evidence is clear: effective treatment for a condition that can cause permanent disability should not be withheld due to theoretical concerns about minimal corticosteroid exposure at term.